Ferring Japan Starts Own Marketing Of Fertility Drug
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Ferring Pharma, a Japanese subsidiary of the Swiss drug maker Ferring Pharmaceuticals, announced July 7 that it will begin its own marketing efforts beginning July 28. Its first product is the fertility drug human menopausal gonadotropin (hMG) injection 75IU. Ferring Pharma has been marketing an ulcerative colitis drug and human growth hormone products through partners, and the company's annual sales are ¥25 billion. With the start of its own marketing, Ferring estimates sales to reach ¥30 billion by 2017, accounting for 10 percent of worldwide sales. The company will focus on infertility and urology as it looks to further widen its product pipeline. Ferring Pharma also started jointly marketing enuresis drug desmopressin with Kyowa Hakko in July. (Click here for more - Japanese language
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.